Kiniksa Pharmaceuticals, Ltd. (KNSA)
NASDAQ: KNSA · IEX Real-Time Price · USD
21.23
+0.07 (0.33%)
Jul 19, 2024, 4:00 PM EDT - Market closed
Kiniksa Pharmaceuticals Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for KNSA stock have an average target of 30.2, with a low estimate of 25 and a high estimate of 34. The average target predicts an increase of 42.25% from the current stock price of 21.23.
Analyst Consensus: Strong Buy
* Price targets were last updated on May 3, 2024.
Analyst Ratings
The average analyst rating for KNSA stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 2 | 2 | 2 | 4 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Buy Initiates $34 | Buy | Initiates | $34 | +60.15% | May 3, 2024 |
| JP Morgan | JP Morgan | Buy Maintains $26 → $30 | Buy | Maintains | $26 → $30 | +41.31% | May 1, 2024 |
| Evercore ISI Group | Evercore ISI Group | Buy Maintains $25 → $30 | Buy | Maintains | $25 → $30 | +41.31% | Apr 24, 2024 |
| Wedbush | Wedbush | Buy Maintains $23 → $25 | Buy | Maintains | $23 → $25 | +17.76% | Jan 2, 2024 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $22 → $32 | Strong Buy | Maintains | $22 → $32 | +50.73% | Jul 26, 2023 |
Financial Forecast
Revenue This Year
398.02M
from 270.26M
Increased by 47.27%
Revenue Next Year
547.89M
from 398.02M
Increased by 37.65%
EPS This Year
-0.11
from 0.20
EPS Next Year
0.60
from -0.11
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 424.2M | 643.8M | 701.4M | 829.5M | 945.0M |
| Avg | 398.0M | 547.9M | 667.4M | 795.0M | 750.8M |
| Low | 369.5M | 479.2M | 633.9M | 749.7M | 461.8M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 57.0% | 61.7% | 28.0% | 24.3% | 18.9% |
| Avg | 47.3% | 37.7% | 21.8% | 19.1% | -5.6% |
| Low | 36.7% | 20.4% | 15.7% | 12.3% | -41.9% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 0.47 | 1.21 | 0.84 | 1.94 | 0.91 |
| Avg | -0.11 | 0.60 | 0.65 | 1.39 | 0.89 |
| Low | -0.45 | -0.21 | 0.42 | 0.86 | 0.85 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 136.3% | - | 41.0% | 197.6% | -34.4% |
| Avg | - | - | 9.6% | 113.3% | -36.3% |
| Low | - | - | -29.3% | 32.1% | -38.8% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.